Metagenomi Therapeutics, Inc. Stock Issued During Period, Value, Conversion of Units
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Metagenomi Therapeutics, Inc. stock issued during period, value, conversion of units for the quarter ending 2024-03-31 was $350.76M.
- Metagenomi Therapeutics, Inc. stock issued during period, value, conversion of units for fiscal 2024 was $350.76M.
| Period end | Stock Issued During Period, Value, Conversion of Units 3 month | Stock Issued During Period, Value, Conversion of Units 12 month |
|---|---|---|
| 2024-12-31 | $350.76M 10-K · filed 2026-03-05 | |
| 2024-03-31 | $350.76M 10-Q · filed 2025-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |